The mouse/human chimeric monoclonal antibody ca2 neutralizes tnf in vitro and protects transgenic mice from cachexia and tnf lethality in vivo

Cytokine

Volumn 7, Issue 1, 1995, Pages 15-25

  Siegel, Scott A ^a,d   Shealy, David J ^a   Nakada, Marian T ^a   Le, Junming ^b   Woulfe, Donna S ^a,e   Probert, Lesley ^c   Kollias, George ^c   Ghrayeb, John ^a   Vilcek, Jan ^b   Daddona, Peter E ^a,f  

^a CENTOCOR INC   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c HELLENIC PASTEUR INSTITUTE   (Greece)

^d Phytera Inc   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f ALZA CORPORATION   (United States)

Author keywords

Tnf cA2 Rheumatoid arthritis

Indexed keywords

CYTOKINE RECEPTOR; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; PROCOAGULANT; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY;

ANIMAL EXPERIMENT; ANTIGEN ANTIBODY REACTION; ANTIGEN EXPRESSION; ARTICLE; CACHEXIA; CELL SECRETION; CONTROLLED STUDY; ENDOTHELIUM CELL; FIBROBLAST; HUMAN; HUMAN CELL; LEUKOCYTE ADHERENCE; MITOGENESIS; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; TRANSGENIC MOUSE; UMBILICAL VEIN; VASCULAR ENDOTHELIUM;

ANIMAL; ANTIBODIES, MONOCLONAL; BLOOD COAGULATION FACTORS; CACHEXIA; CELL ADHESION; CELL ADHESION MOLECULES; CELL DIVISION; CELLS, CULTURED; E-SELECTIN; ENDOTHELIUM, VASCULAR; FIBROBLASTS; GENE EXPRESSION REGULATION; HUMAN; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-6; MICE; MICE, TRANSGENIC; NEUTRALIZATION TESTS; NEUTROPHILS; RECOMBINANT FUSION PROTEINS; RECOMBINANT PROTEINS; RESPIRATORY BURST; TUMOR NECROSIS FACTOR; UMBILICAL VEINS;

EID: 0028964310     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1006/cyto.1995.1003     Document Type: Article

References (53)

1. Beutler B. Cerami A (1988) Tumor necrosis, cachexia, shock and inflammation: a common mediator. Ann Rev Biochem 57:505-18.
2. Vilcek J. Lee TH (1991) Tumor necrosis factor. New insights into the molecular mechanisms of its multiple actions. J Biol Chem 266:7313-7316.
3. Balkwill FR. Burke F (1989) The cvlokine network. Immunol Today 10:299-304.
4. Hesse DG, Tracey KJ, Fong Y, Manogue KR. Palladino Jr MA. Cerami A. Shires GT. Lowry SF (1988) Cytokine appearance in human endotoxemia and primate bacteremia. Surg Gynecol Obstel 166: 147-153.
5. Tracey KJ. Beutler B, Lowry SF. Merryweather J, Wolpe S, Milsark IW, Hariri RJ, Fahey III TJ, Zentella A. Albert JD. Shires GT. Cerami A (1986) Shock and tissue injury induced by recombinant human cachectin. Science 234:470-473.
6. Tracey KJ. Lowry SF, Fahey III TJ. Albert JD. Fong Y. Hesse D. Beutler B. Manogue KR. Calvano S, Wei H. Cerami A. Shires GT (1987) Cachectin/tumor necrosis factor induces lethal shock and stress hormone responses in the dog. Surg Gynecol Obstet 164:415-422.
7. Beutler B. Milsark IW. Cerami AC (1985) Passive immu-nization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 229:869-871.
8. Tracey KJ. Fong Y. Hesse DG. Manogue KR. Lee AT, Kuo GC, Lowry SF. Cerami A (1987) Anti-eachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteremia. Nature 330:662-664.
9. W septic shock following thcrapv with antibody to tumor necrosis factor (TNFa). Circ Shock 30:279-292.
10. Fiers W (1991) Tumor necrosis factor. Characterization at the molecular, cellular and in vivo level. FEBS Letters 285(2): 199-212.
11. Dinarello CA (1992) Interleukin-1 and tumor necrosis factor: effector cytokines in autoimmune diseases. Semin Immunol 4(3): 133-45.
12. Jacob CO (1992) Studies on the role of tumor necrosis factor in murine and human autoimmunity. J Autoimmun 5 Suppl A: 133-43.
13. Harris ED Jr (1990) Rheumatoid arthritis. Pathophysiology and implications for therapy. N Engl J Med 322:1277-1289.
14. Sewell KL. Trcntham DE (1993) Pathogenesis of rheumatoid arthritis. Lancet 341:283-286.
15. Brennan FM. Maini RN and Feldmann M (1992) TNFa-A pivotal role in rheumatoid arthritis? Br J Rheumatol 31:293-98.
16. Kollias G (1993) Tumor necrosis factor: A specific trigger in arthritis. In: 51st Forum in Immunology. TNF in Pathology: old facts and new questions. Research in Immunology. 5:342-347.
17. DiGiovine F. Nuki G. Duff G (1988) Tumor necrosis factor in synovial exudates. Ann Rheum Dis 47:768-772.
18. Saxne T, Palladino MA Jr. Heinegard D. Talal N, Wollheim FA (1988) Detection of tumor necrosis factor a but not tumor necrosis factor [) in rheumatoid arthritis synovial fluid and serum. Arlhr Rheum 31:1041-1045.
19. Brennan FM. Chantry D. Jackson AM. Maini RN. Feldmann M (1989) Cytokine production in culture by cells isolated from the synovial membrane. J Autoimmun 2S: 177-186.
20. Keffer J, Probert L, Cazlaris H. Georgopoulos S, Kaslaris E. Kioussis D. Kollias G (1991) Transgenic mice expressing human tumor necrosis factor: a predictive genetic model of arthritis. EMBO J 10:4025-4031.
21. Brennan FM, Field M, Chu CQ, Feldmann M. Mairvi RN (1991) Cvtokinc expression in rheumatoid arthritis. Br J Rheumatol 30 S 1:76-80.
22. Knight DM. Trinh H. Le J. Siegel S, Shealy D, McDonough M. Scallon B, Moore MA. Viicek J, Daddona P. Ghrayeb J (1993) Construction and initial characterization of a mouse/human chimeric anti-TNF antibody. Mol Immunol 30:1443-53.
23. Derkx B. Taminiau J. Randcma S, Stronkhorst A, Wortel C. Tytgat G, van Deventer S (1993) Tumour-necrosis-factor antibody treatment in Crohn’s disease. Lancet 342:173-174.
24. Elliott MJ, Maini RN. Feldmann M. Long-Fox A, Charles P. Katsikis P. Brennan FM, Walker J, Bijl H. Ghrayeb J, Woody JN (1993) Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor-a. Arthritis Rheum 36. 1681-1690.
25. Probert L. Keffer J. Corbella P, Cazlaris H. Patsavoudi E, Stephens S, Kaslaris E. Kioussis D. Kollias G (1993) Wasting, ischemia and lymphoid abnormalities in mice expressing T cell-targeted human tumor necrosis factor transgenes. J Immunol 151:1894-1906.
26. Vilcek J, Palombella VJ, Henriksen-DeStefano D. Swenson C, Feinman R, Hirai M. Tsujimoto M (1986) Fibroblast growth enhancing activity of tumor necrosis factor and its relationship to other polypeptide growth factors. J Exp Med 163:632-643.
27. 2-Interferon by Tumor Necrosis Factor. A homeostatic mechanism in the control of cell proliferation. Cell 45:659-666.
28. Bevilacqua MP, Pober JS, Majeau GR. Fiers W. Cotran RS, Gimbrone MA Jr (1986) Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of imerleuk.in-1. Proc Natl Acad Sci USA 83:4533-4537.
29. Bevilacqua MP, Stengelin S. Gimbrone MA Jr, Seed B (1989) Endothelial leukocyte adhesion molecule 1: an inducible receptor for neutrophils related to complement regulatory proteins and lectins. Science 243:1160-1165.
30. Pober JS. Lapierre LA. Stolpen AH. Brock TA, Springer TA, Fiers W. Bevilacqua MP, Mendrick DL, Gimbrone MA Jr (1987) Activation of cultured human endothelial cells by recombinant lymphotoxin: comparison with tumor necrosis factor and interleukin-1 specics. J Immunol 138:3319-3324.
31. Gamble JR, Harlan JM. Klebanoff SJ, Vadas MA (1985) Stimulation of the adherence of neutrophils to umbilical vein endothelium bv human recombinant tumor necrosis factor. Proc Natl Acad Sci USA 82:8667-8671.
32. Berkow RL, Wang D, Larrick JW. Dodson RW, Howard TH (1987) Enhancement of neutrophil Superoxide production by prcincubation with recombinant human tumor necrosis factor. J Immunol 139:3783-3791.
33. Mackay F. Loetscher H, Stueber D, Gehr G, Lesslauer W (1993) Tumor necrosis factor a (TNF-a)-induced cell adhesion to human endothelial cells is under dominant control of one TNF receptor type, TNF-R55. J Exp Med 177:1277-1286.
34. Pennington JE (1993) Therapy with antibody to tumor necrosis factor in sepsis. Clin Infect Dis 17 (Suppl 2):5515-5519.
35. Feldmann M, Brennan FM, Chantry D. Haworth C, Turner M. Abney E, Buchan G, Barrett K, Barkley D, Chu A, Field M, Maini RN (1990) Cytokine production in the rheumatoid joint: implications for treatment. Ann Rheum Dis 49:480-486.
36. Gitter BD, Labus JM. Lees SL, Scheetz ME (1989) Char-acteristics of human synovial fibroblast activation by IL-lβ and TNFa. Immunology 66:196-200.
37. Chu CO, Field M. Feldmann M, Maini RN (1991) Localization of tumor necrosis factor a in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum 34:1125-1132.
38. 2 production bv human synovial cells and dermal fibroblasts. J Exp Med 162:2163-2168.
39. Saklatvala J (1986) Tumor necrosis factor a stimulates resorption and inhibits synthesis or proteoglycan in cartilage. Nature 322:547-549.
40. Bettolini DR, Nedwin GE. Bringman TS, Smith DD. Mundy GR (1986) Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature 319:516-518.
41. Williams RO, Feldmann M, Maini RN (1992) Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 89:9784-9788.
42. Brennan FM, Chantry D, Jackson A. Maini RN. Feldmann M (1989) Inhibitory cffect of TNFa antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancct ii:244-247.
43. Haworth C, Brennan FM, Chantry D, Turner M, Maini RN, Feldmann M (1991) Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-a. Eur J Immunol 21:2575-2579.
44. Nawroth PP, Bank I, Handley D. Cassimeris J, Chess L, Stem D (1986) Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin-1. J Exp Med 163:1363-1375.
45. Dinarcllo CA. Cannon JG, Wolff SM. Bernhcim HA, Beutler B, Cerami A. Figari IS. Pailadino MA Jr, O’Connor JV (1986) Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin-1. J Exp Med 163:1433-1450.
46. 2). as a B cell hybridoma/plasmacytoma growth factor induced by interleukin-1 and tumor necrosis factor. J Exp Med 165:914-919.
47. Seelentag WK. Mcrmod J-J, Montesano R. Vassalli P (1987) Additive effects of interleukin-1 and tumor necrosis factor-a on the accumulation of the three granulocyte and macrophage colon-stimulating factor mRNAs in human endothelial cells. EMBO J 6:2261-2265.
48. Murch SH, Lamkin VA, Savage MO. Walker Smith JA. MacDonald TT (1991) Scrum concentrations of tumour necrosis factor-a in childhood chronic inflammatory bowel disease. Gut 32:913-917.
49. Braegger CP, Nicholls S, Murch SH. Stephens S, MacDonald TT (1992) Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancct 339:89-91.
50. Ruddle NH. Bergman CM. McGrath KM. Lingenhcld EG, Grunnet ML, Padula SJ, Clark RB (1990) An antibody to lymphotoxin and tumor nccrosis factor prevents transfer of experimental allergic encephalomyelitis. J Exp Med 172:1193-1200.
51. Brocke S, Gaur A, Piercy C. Gautam A, Gijbcls K, Fathman CG, Steinman L (1993) Induction of relapsing paralysis in experimental autoimmune encephalomyelitis by bacterial superantigen. Nature 365:642-644.
52. Bagby GJ. Plessala KJ, Wilson LA, Thompson JJ, Nelson S (1991) Divergent efficacy of antibody to tumor necrosis factor-a in intravascular and peritonitis models of sepsis. J Inf Dis 163:83-88.
53. Metcalf JA. Galiin JI. Nauseef WM, Root RK (1986) Laboratory Manual of Neutrophil Function, Raven Press, New York.